Trials / Terminated
TerminatedNCT03458416
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Radius Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 8 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in participants with Prader-Willi Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cannabidiol Oral Solution | An oral solution containing pharmaceutical grade cannabidiol (nonplant-based). |
Timeline
- Start date
- 2018-09-06
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
- First posted
- 2018-03-08
- Last updated
- 2023-06-22
- Results posted
- 2023-06-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03458416. Inclusion in this directory is not an endorsement.